

## Special Issue

# Bryozoan Metabolites and Their Pharmacological Activities

### Message from the Guest Editors

The phylum Bryozoa comprises ~6000 described extant species from freshwater and marine environment. Despite this great biodiversity, the chemistry of this group has been poorly investigated in comparison with other invertebrates. Indeed, only 26 species have been investigated to date, revealing ca 300 molecules, indicating bryozoans as a rich source of novel chemical entities, only partially screened. In addition, most of the bryozoans compounds isolated so far, including the well-known bryostatins, have shown a wide spectra of pharmacological properties such as anticancer, antiparasitic, antiviral, and neurological activities, suggesting significant biomedical potential. To increase interest in this underexplored group of organisms, the Special Issue "Bryozoan Metabolites and their Pharmacological Activities" will collect original papers, as well as reviews, focused on bryozoans natural product chemistry and bioactivity. Studies on bryozoans symbionts are welcome too.

### Guest Editors

Dr. Maria Letizia Ciavatta

National Research Council (CNR) - Institute of Biomolecular Chemistry (ICB), Pozzuoli, Italy

Dr. Marianna Carbone

National Research Council (CNR) - Institute of Biomolecular Chemistry (ICB), Pozzuoli, Italy

### Deadline for manuscript submissions

closed (10 March 2022)



## Marine Drugs

an Open Access Journal  
by MDPI

Impact Factor 5.4  
CiteScore 10.1  
Indexed in PubMed



[mdpi.com/si/80239](https://mdpi.com/si/80239)

*Marine Drugs*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[marinedrugs@mdpi.com](mailto:marinedrugs@mdpi.com)

[mdpi.com/journal/  
marinedrugs](https://mdpi.com/journal/marinedrugs)





# Marine Drugs

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.4  
CiteScore 10.1  
Indexed in PubMed



[mdpi.com/journal/  
marinedrugs](https://mdpi.com/journal/marinedrugs)



## About the Journal

### Message from the Editor-in-Chief

During the past few decades there has been an ever increasing number of novel compounds discovered in the marine environment. This is exemplified by the robust preclinical and clinical pipeline that currently exists for marine natural products. *Marine Drugs* is inviting contributions on new advances in marine biotechnology, pharmacology, chemical ecology, synthetic biology, and genomics approaches related to the discovery of therapeutically relevant marine natural products. Our goal is to share your contribution in a timely fashion and in a manner that will be valued by the scientific community.

---

### Editor-in-Chief

Prof. Dr. Bill J. Baker

Department of Chemistry, University of South Florida, 4202 E. Fowler Ave., CHE 205, Tampa, FL 33620-5250, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, MarinLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmacology, Toxicology and Pharmaceutics (miscellaneous))